EDGAR·FLOW

Evommune, Inc. — Form 8-K

Filed November 17, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 28/100
What the filing says
Evommune filed an 8-K on November 17, 2026 disclosing Item 5.02 (departure of directors/officers and compensatory arrangements). The filing header references these events but the actual detailed text with specific names, titles, dates, severance amounts, equity adjustments, and other material terms is not provided in the excerpt supplied. No counterparties, dollar amounts, percentages, share counts, or concrete changes can be identified from the available filing extract.
Why this rating

Cannot assess substance without actual disclosure text. Item 5.02 routine; officer changes are common. Relative to $302M asset base, impact depends on role seniority—data absent.

Extracted items
View original filing on SEC.gov ↗ EVMN · stock on Yahoo Finance ↗

See more from November 17, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.